Timber Pharmaceuticals Inc Down 0.50% To $2.98 After Earnings

Tuesday, August 22, 2023 - Timber Pharmaceuticals Inc (TMBR) reported downside earnings and in line revenues.

Timber Pharmaceuticals Inc's earnings came in at an EPS loss of $1.32 per share. The firm's loss per share narrowed by 82% since reporting a loss of $7.5 per share a year ago.

Revenues were in line at $0.00. That revenue figure is unchanged from the year ago report from the year ago quarter.

The stock is down 0.50% to $2.98 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Timber Pharmaceuticals Inc has been a strong performer over the past few months, garnering a high Long-Term Technical Rank by InvestorsObserver of 95, putting Timber Pharmaceuticals Inc in the top 25% of stocks. The firm set a 52-week low on December 27, 2022 at $1.2 and set a 52-week high on September 14, 2022 at $8.73.

Timber Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. It is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and scleroderma. The company's development pipeline includes TMB-001 (Topical Isotretinoin), TMB-002 (Topical Rapamycin), and TMB-003 (Topical / Subcutaneous ET-A Receptor Antagonist).